title: A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization.
abstract: BACKGROUND
  Currently, most therapies of postembolization syndrome following transcatheter arterial chemoembolization (TACE) aim directly at a single symptom, thus leading to limitations.
  
  
  OBJECTIVE
  To seek for a systematic approach to prevent and treat the syndrome, we carried out this study to observe the effect of ginsenosides (GS) and dexamethasone (Dex) in alleviating the postembolization syndrome following TACE.
  
  
  METHODS
  In the randomized, double-blinded and controlled trial, 120 patients with primary liver cancer were divided into 4 groups, with 30 patients in each group. The changes of clinical symptoms and laboratory tests before TACE and on 3 and 7 days after TACE were observed.
  
  
  RESULTS
  The results indicated that Dex combined with GS not only markedly decreased the occurrence ratio and duration of such symptoms as nausea, vomiting, and fever, but also significantly reduced levels of total bilirubin, glutamic oxaloacetic transaminase, and glutamic-pyruvic transaminase (AST) and improved the Child-Pugh stage of liver function as compared with single use of GS or Dex.
  
  
  CONCLUSIONS
  In conclusion, although single use of Dex or GS may improve some indices of adverse effects after TACE, the combination of Dex and GS can systematically prevent and treat the postembolization syndrome following TACE.
authors.affiliation: The Department of Traditional Chinese Medicine in Chinghai, Hospital of the Second Military Medicine University, Shanghai, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Yinglu
authors.forename: Ling
authors.initials: L
authors.lastname: Changquan
authors.forename: Zhai
authors.initials: Z
authors.lastname: Xiaofeng
authors.forename: Li
authors.initials: L
authors.lastname: Bai
authors.forename: Zhu
authors.initials: Z
authors.lastname: Dezeng
authors.forename: Chen
authors.initials: C
authors.lastname: Zhe
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects* / Q000379:methods; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000188:drug therapy / Q000209:etiology; D036145:Ginsenosides / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy / Q000209:etiology; D005894:Panax / Q000737:chemistry*; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D014839:Vomiting / Q000188:drug therapy / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents; D036145:Ginsenosides; D010936:Plant Extracts; D003907:Dexamethasone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin